Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study Data indicate a potentially favorable safety profile with a lower incidence of Cytokine Release Syndrome Encouraged by the positive data, Harley Street Healthcare Group along with its partners intends to commit resources to set up a Global Cancer Initiative wi ...